Related Experiment Video
Updated: Feb 22, 2026
Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts
Published on: March 22, 2017
(Re-)programming of subtype specific cardiomyocytes
Frauke Hausburg1, Julia Jeannine Jung1, Matti Hoch2
1Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Department of Cardiac Surgery, Rostock University Medical Center, Schillingallee 69, 18057 Rostock, Germany; Department Life, Light and Matter of the Interdisciplinary Faculty at Rostock University, Albert-Einstein-Straße 25, 18059 Rostock, Germany.
Abstract:
Adult cardiomyocytes (CMs) possess a highly restricted intrinsic regenerative potential - a major barrier to the effective treatment of a range of chronic degenerative cardiac disorders characterized by cellular loss and/or irreversible dysfunction and which underlies the majority of deaths in developed countries. Both stem cell programming and direct cell reprogramming hold promise as novel, potentially curative approaches to address this therapeutic challenge. The advent of induced pluripotent stem cells (iPSCs) has introduced a second pluripotent stem cell source besides embryonic stem cells (ESCs), enabling even autologous cardiomyocyte production. In addition, the recent achievement of directly reprogramming somatic cells into cardiomyocytes is likely to become of great importance. In either case, different clinical scenarios will require the generation of highly pure, specific cardiac cellular-subtypes. In this review, we discuss these themes as related to the cardiovascular stem cell and programming field, including a focus on the emergent topic of pacemaker cell generation for the development of biological pacemakers and in vitro drug testing.
Insights
Cardiovascular regenerative medicine faces challenges due to limited cardiomyocyte regeneration. Stem cell and direct cell reprogramming offer promising therapeutic strategies for cardiac repair and developing biological pacemakers.
Area of Science:
- Cardiovascular Biology
- Regenerative Medicine
- Stem Cell Science
Background:
- Adult cardiomyocytes (CMs) have limited regenerative capacity, hindering treatments for heart disease.
- Chronic degenerative cardiac disorders result in cellular loss and dysfunction, leading to high mortality.
- Stem cell-based therapies and direct cell reprogramming are emerging as potential curative approaches.
Purpose of the Study:
- To review advancements in cardiovascular stem cell and reprogramming research.
- To explore the generation of specific cardiac cell subtypes, including pacemaker cells.
- To discuss applications in biological pacemakers and in vitro drug testing.
Main Methods:
- Review of induced pluripotent stem cells (iPSCs) as a source for cardiomyocyte production.
- Discussion of direct somatic cell reprogramming into cardiomyocytes.
- Focus on generating pure, specific cardiac cellular subtypes.
Main Results:
- Induced pluripotent stem cells (iPSCs) provide an alternative to embryonic stem cells (ESCs) for autologous cardiomyocyte generation.
- Direct reprogramming of somatic cells into cardiomyocytes is a significant development.
- The generation of specific cardiac cell subtypes is crucial for clinical applications.
Conclusions:
- Stem cell programming and direct cell reprogramming hold significant promise for treating heart disease.
- The development of biological pacemakers and improved in vitro drug testing models are key applications.
- Generating pure cardiac cell subtypes is essential for advancing cardiovascular regenerative medicine.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
10:05Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
Published on: November 13, 2015
